Search research articles
Contact Us
Filters
Showing results (131-140 of 199) with videos related to
Page
of 20
Sort By:
Journal of Neuroendocrinology
|
June 25, 2026
Response to "Methodological and inferential limits before abandoning follow-up in node-negative typical lung carcinoids"
Tobias Stemann Lau, Patrick Soldath, Karina Stubkjær Rewitz, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 28, 2011
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience
Ingrid Holst Olsen, Seppo W Langer, Ida Jepsen, et al.
Journal of Neuroendocrinology
|
March 19, 2026
Follow-up is not justified in patients with typical lung carcinoids without lymph node involvement treated with curative intent: A Danish Multi-ENETS Center of Excellence Study
Tobias Stemann Lau, Patrick Soldath, Karina Stubkjær Rewitz, et al.
Ugeskrift for Laeger
|
October 5, 2016
[Cardiovascular complications following thoracic radiotherapy in patients with cancer]
Kirsten Melgaard Nielsen, Julie I Helene Borchsenius, Birgitte Vrou Offersen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 27, 2021
Semiautomatic Tumor Delineation for Evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume
Esben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, et al.
Molecular Imaging and Biology
|
February 15, 2022
Activity Dose Reduction in <sup>64</sup>Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability
Mathias Loft, Esben A Carlsen, Camilla B Johnbeck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 11, 2023
An Investigation of Lesion Detection Accuracy for Artificial Intelligence-Based Denoising of Low-Dose <sup>64</sup>Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms
Mathias Loft, Claes N Ladefoged, Camilla B Johnbeck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 17, 2020
<sup>18</sup>F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study
Tina Binderup, Ulrich Knigge, Camilla Bardram Johnbeck, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 26, 2016
Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer
Lotte Nygård, Ivan R Vogelius, Barbara M Fischer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 8, 2026
Malignancy Detection Rates of [<sup>68</sup>Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer
Tine N Christensen, Seppo W Langer, Danijela Dejanovic, et al.
Page
of 20
Search research articles
Search
Showing results (131-140 of 199) with videos related to
Sort By:
Page
of 20
Journal of Neuroendocrinology
|
June 25, 2026
Response to "Methodological and inferential limits before abandoning follow-up in node-negative typical lung carcinoids"
Tobias Stemann Lau, Patrick Soldath, Karina Stubkjær Rewitz, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 28, 2011
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience
Ingrid Holst Olsen, Seppo W Langer, Ida Jepsen, et al.
Journal of Neuroendocrinology
|
March 19, 2026
Follow-up is not justified in patients with typical lung carcinoids without lymph node involvement treated with curative intent: A Danish Multi-ENETS Center of Excellence Study
Tobias Stemann Lau, Patrick Soldath, Karina Stubkjær Rewitz, et al.
Ugeskrift for Laeger
|
October 5, 2016
[Cardiovascular complications following thoracic radiotherapy in patients with cancer]
Kirsten Melgaard Nielsen, Julie I Helene Borchsenius, Birgitte Vrou Offersen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 27, 2021
Semiautomatic Tumor Delineation for Evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume
Esben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, et al.
Molecular Imaging and Biology
|
February 15, 2022
Activity Dose Reduction in <sup>64</sup>Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability
Mathias Loft, Esben A Carlsen, Camilla B Johnbeck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 11, 2023
An Investigation of Lesion Detection Accuracy for Artificial Intelligence-Based Denoising of Low-Dose <sup>64</sup>Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms
Mathias Loft, Claes N Ladefoged, Camilla B Johnbeck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 17, 2020
<sup>18</sup>F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study
Tina Binderup, Ulrich Knigge, Camilla Bardram Johnbeck, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 26, 2016
Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer
Lotte Nygård, Ivan R Vogelius, Barbara M Fischer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 8, 2026
Malignancy Detection Rates of [<sup>68</sup>Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer
Tine N Christensen, Seppo W Langer, Danijela Dejanovic, et al.
Page
of 20